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For the future success of clinical hyperthermia in multimodal 
cancer therapy specifically in combination with radiotherapy 
a concentrated and coordinated effort in all domains is 
needed. Input must come from biology (e.g. 
thermoradiobiology, thermoimmunonology), medical physics 
(e.g. noninvasive thermometry, treatment planning), 
engineering (e.g. novel hardware for intensity modulated 
hyperthermia and image guided hyperthermia), IT (e.g. 
optimization and synergy of RT and HT-workflow); and clinics 
(phase I/II study in large animal with spontaneous tumors and 
for human patients with novel technology, 
multicenter/international randomized phase III studies for 
common tumours with stringent QA criteria). 
Key issues are: 
1.       Why, despite a sound thermoradiobiological rationale 
is clinical implementation of HT so slow?  
2.        Why is innovation and progress in the development of 
timely hardware and software technology so slow, 
specifically if compared to the recent progress in radiation 
oncology technology?  
3.       Why did hyperthermia not get a better integration into 
clinical protocols using state of the art radiation therapy 
technology?  
4.       What are the promises of thermoablative procedures 
like HIFU, RFA, or nanotechnology based hyperthermia 
compared to classical regional (capacitive or radiative) 
hyperthermia used as physical radio sensitizer? 
An international coordinated effort is needed with active 
participation of all stakeholders. Local institutional 
innovations are desperately needed from interested industrial 
partners, academic centers focusing on technology 
development and academic centers focusing on novel clinical 
trial design. This could provide optimal synergism and pave 
the way toward implementation of oncology hyperthermia as 
a standard treatment modality within multimodal cancer 
therapy. 
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Hyperthermia methods can be subdivided into local, 
locoregional and whole body heating, and in different 
temperature ranges either aiming for direct ablation 
(T>55°C, only for local heating) or for radiosensitization and 
chemosensitization (39°C<T<43°C, all three categories). The 
application of hyperthermia should always be guided by 
sufficient thermometry during treatment to ensure that the 
intended thermal dose is given to the entire target region. 
This is challenging due to tissue and blood flow 
heterogeneities which can affect the uniformity of the 
thermal dose distribution. 
Achieving a uniform temperature rise of 39-42°C is 
straightforward for whole body heating techniques, but more 
challenging for local and locoregional hyperthermia. Most 
clinical hyperthermia equipment uses radiofrequency (RF) 
and microwave (MW) antennas for local and locoregional 
heating of tumors. Deep seated tumors are heated with 
phased arrays of RF/MW antennas. The frequencies of 70-
150MHz used for heating deep seated tumors result in heating 
of the tumor and a large margin around the tumor. The trend 
is to increase both the frequency and the number of antennas 
in order to reduce the focus size and thus achieve more 
selective tumor heating. Temperature measurements are 
performed with a limited number of invasive temperature 
probes, these are now increasingly supplemented with non-
invasive temperature measurements using MRI and other 
techniques which yield a 3-D image of the temperature 
distribution. 
Tumor ablation is achieved with invasive interstitial RF, MW 
and ultrasound (US) techniques. A more recent non-invasive 
technique is High Intensity Focused Ultrasound (HIFU) 
combined with non-invasive MRI thermometry. HIFU is 
capable of focusing heating to regions <1cm, the use of HIFU 
to achieve uniform heating of a large region to 40-43°C is 
presently investigated.  
Reliable hyperthermia treatment planning is important for 
pre-treatment planning, adaptive planning during treatment 
and for reconstruction of the given thermal dose distribution 
after treatment. A challenge for hyperthermia treatment 
planning is to model both the energy absorption in the tissue 
and the bio heat transfer by tissue blood flow, and the latter 
may also change during treatment. The latest planning 
systems are capable of fast and high resolution computations, 
sufficiently fast for real time computation during treatment, 
e.g. to adapt settings in response to changing blood flow 
values. 
Conclusion: hyperthermia equipment is increasingly capable 
of providing a well-controlled dose distribution similar to 
standards in radiation oncology. This well-controlled dose 
distribution is essential in achieving optimal clinical results. 
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Hyperthermia (HT) serves as a safe adjuvant treatment to 
radiotherapy in order to enhance its clinical results 
(radiosensitisation). It causes usually no or minimal injury to 
normal tissues. The best approach is to deliver hyperthermia 
and radiation simultaneously, which is difficult in common 
practice. The above is supported with extensive preclinical 
data and a number of randomized clinical trials concerning 
mainly combination of different types of hyperthermia 
treatment with standard external beam radiotherapy of 
specific types of cancer. Unfortunately, brachytherapy based 
HT treatment is quite poorly investigated and these data are 
scarce. Nevertheless, a short subjective literature review will 
be presented. Then, some possible clinical applications will 
be discussed, e.g. superficial or interstitial local/regional HT 
